Nov 21, 2024 · 1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer (SCLC). 2. Durvalumab had a tolerable safety profile, with a comparable incidence of adverse effects to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Small

Nov 25, 2024 · CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The Latest In a phase 2, randomized, double-blind, placebo-controlled study done by Intellia Therapeutics the efficacy and safety of NTLA-2002 was tested. The study involved 27 participants who were randomized to receive either a 25mg dose,

Title Year Journal Citations Key findings; The UKPDS: Reducing the risk of diabetes-related morbidity and mortality: 1998: Lancet: 20,000: 1. For patients with type 2 diabetes mellitus, pharmacologic blood glucose control with sulfonylureas or insulin significantly reduces the risk of microvascular complications, but not macrovascular complications

Nov 26, 2024 · 1. In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, finerenone treatment was associated with lower rates of worsening heart failure events. 2. Finerenone treatment was not associated with an increase in serious adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Finerenone, a nonsteroidal mineralocorticoid ...

Nov 18, 2024 · 1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the cetuximab group with HR 1.33 (non-significant). 2. Regarding safety, grade 3-4 adverse events occurred in 61% for durvalumab and 79% for cetuximab. Evidence Rating Level: 1 (Excellent) Study Rundown: Concurrent radiotherapy with cisplatin is the standard treatment for locoregionally advanced

Dec 10, 2024 · 1. In this randomized controlled trial, in older adults with non-ST-segment elevation myocardial infarction (NSTEMI), invasive treatment did not significantly reduce the composite risk of cardiovascular death or nonfatal MI compared to conservative treatment. 2. There were fewer occurrences of fatal or nonfatal MI in patients in the invasive-strategy group than in the conservative-strategy group.

Oct 9, 2024 · 1. In this randomized controlled trial of men aged 50 to 60, forgoing prostate biopsies in those with elevated PSA but negative MRI reduced the diagnosis of clinically insignificant cancer. 2. MRI-negative men who did not undergo prostate biopsy did not have higher rates of incurable cancer diagnoses in follow-up screenings. Evidence Rating Level: 1

Oct 28, 2024 · 1. The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not associated with increased risks of pulmonary aspiration during upper gastrointestinal endoscopy discontinuation compared to the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors. 2. The use of GLP-1 receptor agonists among adults with T2DM was associated

Nov 16, 2024 · 1. In this randomized clinical trial comparing the use of pelvic floor muscle training (PFMT) alone to PFMT with a biofeedback (BF) device, the use of PFMT with BF was superior in reducing stress urinary incontinence (SUI) in postpartum women. Evidence Rating Level: 1 (Excellent) Stress urinary incontinence (SUI) is a pelvic floor dysfunction disorder

Sep 9, 2024 · In-Depth [randomized controlled trial]: This phase 3, multicenter, open-label trial enrolled adults with stage IV clear-cell renal-cell carcinoma who had disease progression after treatment with immunotherapy and a VEGFR-TKI and randomized them (1:1) to belzutifan (n=374) or everolimus (n=372). Median follow-up time was 18.4 months for the first interim analysis and 25.7 months for the second ...